Department of Nutrition and Movement Sciences, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.
Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Maastricht, The Netherlands.
Obesity (Silver Spring). 2021 Sep;29(9):1423-1426. doi: 10.1002/oby.23221. Epub 2021 Aug 2.
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) uses the host's angiotensin-converting enzyme 2 (ACE2) as a cellular entry point. Therefore, modulating ACE2 might impact SARS-CoV-2 viral replication, shedding, and coronavirus disease 2019 (COVID-19) severity. Here, it was investigated whether the angiotensin II type 1 receptor blocker valsartan alters the expression of renin-angiotensin system (RAS) components, including ACE2, in human adipose tissue (AT) and skeletal muscle.
A randomized, double-blind, placebo-controlled clinical trial was performed, in which 36 participants (BMI 31.0 ± 0.8 kg/m ) with impaired glucose metabolism received either valsartan or placebo for 26 weeks. Before and after 26 weeks' treatment, abdominal subcutaneous AT and skeletal muscle biopsies were obtained, and gene expression of RAS components was measured by quantitative reverse transcription polymerase chain reaction.
Valsartan treatment did not significantly impact the expression of RAS components, including ACE2, in AT and skeletal muscle.
Given the pivotal role of ACE2 in SARS-CoV-2 spread and the clinical outcomes in COVID-19 patients, the data suggest that the putative beneficial effects of angiotensin II type 1 receptor blockers on the clinical outcomes of patients with COVID-19 may not be mediated through altered ACE2 expression in abdominal subcutaneous AT.
严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）利用宿主的血管紧张素转换酶 2（ACE2）作为细胞进入点。因此，调节 ACE2 可能会影响 SARS-CoV-2 病毒复制、脱落和 2019 年冠状病毒病（COVID-19）的严重程度。在这里，研究了血管紧张素 II 型 1 型受体阻滞剂缬沙坦是否会改变人类脂肪组织（AT）和骨骼肌中肾素-血管紧张素系统（RAS）成分的表达，包括 ACE2。
进行了一项随机、双盲、安慰剂对照的临床试验，其中 36 名（BMI 31.0±0.8kg/m ）代谢受损的参与者接受缬沙坦或安慰剂治疗 26 周。在 26 周治疗前后，获取腹部皮下 AT 和骨骼肌活检，并通过定量逆转录聚合酶链反应测量 RAS 成分的基因表达。
缬沙坦治疗并未显著影响 AT 和骨骼肌中 RAS 成分的表达，包括 ACE2。
鉴于 ACE2 在 SARS-CoV-2 传播和 COVID-19 患者临床结局中的关键作用，这些数据表明血管紧张素 II 型 1 型受体阻滞剂对 COVID-19 患者临床结局的可能有益作用可能不是通过改变腹部皮下 AT 中的 ACE2 表达介导的。
